Cell and Gene Therapy Approvals in China: Latest Regulatory Updates
Decision brief
Answer first · skim in under a minute
China's NMPA has approved multiple cell and gene therapies in 2024, signaling a shift toward faster regulatory pathways. This article covers key approvals, implications for pharma teams, and an FAQ section.
Cell and gene therapy approvals in China are accelerating under NMPA and CDE guidance, with concrete 2025 examples such as conditional approval of ciltacabtagene autoleucel (Carvykti). For gene therapy and CAR-T partners, the story is less about rumor lists and more about published NMPA notices, IND volume, and technical guidelines that now cover hematologic CAR-T and thalassemia gene therapy trials.
Contents9 sections
Key Takeaways
- NMPA conditionally approved ciltacabtagene autoleucel (Carvykti) on February 19, 2025, for relapsed/refractory multiple myeloma after ≥3 prior lines.
- Nature Reviews Drug Discovery (2025) documents NMPA/CDE CGT guideline build-out and maps hundreds of CGT IND filings from 2017–2025 Q2.
- Unverified September 2024 “Landmark Bio / AlloCAR-T” approval claims in older drafts are removed pending matching NMPA primary notices.
- FDA CGT resources remain useful comparators for CMC and clinical expectations when structuring China–global bridging plans.
What did NMPA approve for Carvykti in February 2025?
According to the NMPA English notice dated February 19, 2025, ciltacabtagene autoleucel injection (trade name 卡卫荻 / Carvykti) from Nanjing Legend Biotech was approved for marketing with conditions. The indicated population is adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy who have progressed, including exposure to a proteasome inhibitor and an immunomodulatory agent.
The product is an autologous BCMA-directed CAR-T manufactured with a lentiviral vector—placing it squarely in China’s growing commercial CGT set rather than a research-only pathway.
How are China CGT guidelines and IND volume changing?
A 2025 Nature Reviews Drug Discovery article on China’s CGT trends describes NMPA’s Drug Regulatory Science Action Plan and a suite of CDE technical guidelines issued over about five years spanning CMC, nonclinical studies, clinical pharmacology, and clinical trials. Supplementary materials summarized trial guidance for hematologic CAR-T products (2024) and gene therapy for thalassemia (2025).
The same analysis maps on the order of 765 CGT INDs plus supplemental applications through 2025 Q2 across somatic cell therapy, stem cells, oncolytic microbes, gene therapy, and therapeutic vaccines—evidence of sustained pipeline pressure on CDE reviewers.
What does peer-reviewed literature say about China’s innovation pace?
A 2025 Signal Transduction and Targeted Therapy review discusses China’s rise in first-in-class biologics and CGT, noting a marked increase in CGT clinical-trial registrations (citing 81 in 2023 versus 46 in 2022 in that paper’s dataset). Priority review pathways have helped domestic CAR-T products for relapsed/refractory ALL and multiple myeloma reach patients earlier.
- Carvykti conditional approval: February 19, 2025 (NMPA)
- Nature CGT IND mapping through 2025 Q2: ~765 INDs
- Literature-cited CGT trial registrations: 46 in 2022 vs 81 in 2023
How should global teams use FDA CGT references?
The U.S. FDA’s overview of cellular and gene therapy products remains a practical comparator for potency, comparability, and long-term follow-up expectations. Teams running China–ex-China programs should map NMPA/CDE guideline clauses to FDA CBER expectations early to avoid duplicate CMC work.
What remains unproven or was removed
Earlier draft language claiming September 15, 2024, NMPA approvals of “Oxecabtagene Autoleucel” from Landmark Bio and an unnamed CBMG allogeneic CAR-T is not supported by the NMPA English notices reviewed for this update and has been deleted. ASCPT “48 first-in-class in 2024” figures are also not restated without a primary NMPA statistical bulletin.
Related NovaPharma coverage
Frequently Asked Questions
Which CAR-T did China NMPA approve in February 2025?
On February 19, 2025, NMPA announced conditional marketing approval of ciltacabtagene autoleucel (Carvykti / 卡卫荻) from Nanjing Legend Biotech for adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy.
How is China’s CGT regulatory framework evolving?
A 2025 Nature Reviews Drug Discovery analysis notes NMPA/CDE technical guidelines covering CMC, nonclinical, clinical pharmacology, and clinical studies for CGT, plus mapping of hundreds of CGT IND applications from 2017 through mid-2025.
What should BD teams verify before citing China CGT approvals?
Confirm the product name, sponsor, indication, and approval date on english.nmpa.gov.cn or CDE disclosures. Do not rely on unsourced secondary lists of September 2024 allogeneic CAR-T approvals without a matching NMPA notice.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…